Increased localization of APP-C99 in mitochondria-associated ER
membranes causes mitochondrial dysfunction in Alzheimer disease by Pera, Marta et al.
Article
Increased localization of APP-C99 in mitochondria-
associated ER membranes causes mitochondrial
dysfunction in Alzheimer disease
Marta Pera1,†, Delfina Larrea1, Cristina Guardia-Laguarta2, Jorge Montesinos1, Kevin R Velasco1,
Rishi R Agrawal3, Yimeng Xu2, Robin B Chan2, Gilbert Di Paolo2,‡, Mark F Mehler4, Geoffrey S Perumal5,
Frank P Macaluso5, Zachary Z Freyberg6, Rebeca Acin-Perez7, Jose Antonio Enriquez7, Eric A Schon1,8 &
Estela Area-Gomez1,*
Abstract
In the amyloidogenic pathway associated with Alzheimer disease
(AD), the amyloid precursor protein (APP) is cleaved by b-secretase
to generate a 99-aa C-terminal fragment (C99) that is then cleaved
by c-secretase to generate the b-amyloid (Ab) found in senile
plaques. In previous reports, we and others have shown that
c-secretase activity is enriched in mitochondria-associated endo-
plasmic reticulum (ER) membranes (MAM) and that ER–mitochon-
drial connectivity and MAM function are upregulated in AD. We
now show that C99, in addition to its localization in endosomes,
can also be found in MAM, where it is normally processed rapidly
by c-secretase. In cell models of AD, however, the concentration of
unprocessed C99 increases in MAM regions, resulting in elevated
sphingolipid turnover and an altered lipid composition of both
MAM and mitochondrial membranes. In turn, this change in mito-
chondrial membrane composition interferes with the proper
assembly and activity of mitochondrial respiratory super-
complexes, thereby likely contributing to the bioenergetic defects
characteristic of AD.
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Introduction
Familial AD (FAD) is characterized by mutations in presenilin-1
(PS1), presenilin-2 (PS2), and amyloid precursor protein (APP). APP
is first cleaved by either a-secretase or b-secretase (BACE1) to
produce C-terminal fragments (CTFs) 83 aa (C83) or 99 aa (C99)
long, respectively. PS1 and PS2 are the catalytic subunits of the
c-secretase complex that cleaves C83 and C99 to produce either p3
or b-amyloid (Ab; ~40 aa), respectively, along with the APP intracel-
lular domain (AICD). The accumulation of Ab, and especially its
longer forms (e.g., ~42 aa), within plaques, together with Tau
tangles, are the neuropathological hallmarks of AD. The deleterious
effects of Ab deposition during the symptomatic stages of AD are
undeniable (Hardy & Higgins, 1992), but the role of Ab in earlier
phases of the disease is still debated.
During these early stages, AD cells exhibit alterations in numer-
ous metabolic processes (McBrayer & Nixon, 2013; Wang et al,
2014). Among these, perturbed mitochondrial function, including
reduced respiratory chain activity and ATP production, and
increased oxidative stress (Du et al, 2010), have been described
extensively (Swerdlow et al, 2014), occurring before the appearance
of plaques (Yao et al, 2009; Wang et al, 2014). Nevertheless, the
cause of the mitochondrial deficits in AD is still unknown.
In addition to mitochondrial dysfunction, alterations in lipid
metabolism are another feature of AD (Mapstone et al, 2014), but
their origin and relationship to APP metabolism are unclear. Among
these alterations, abnormal sphingolipid metabolism has been
reported in AD tissues (van Echten-Deckert & Walter, 2012). Specifi-
cally, there is an upregulation of de novo ceramide synthesis
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(Grimm et al, 2011) and an increase in the activity of sphingomyeli-
nase (SMase), which catabolizes sphingomyelin (SM) into ceramide
(Filippov et al, 2012). These alterations act synergistically to
increase ceramide content in AD brains (Filippov et al, 2012).
As these metabolic alterations occur early in AD, they cannot be
explained by the accumulation of plaques or tangles. Moreover,
unsuccessful efforts directed toward modifying Ab production as a
treatment for AD (Castello et al, 2014) have raised the possibility
that other aspects of APP cleavage may be contributing to these
metabolic changes. In this regard, increased levels of the C99 frag-
ment have also been shown to contribute to AD pathogenesis (Lee
et al, 2006; Lauritzen et al, 2012), suggesting a role for C99 in the
early stages of pathogenesis.
The processing of APP occurs in lipid raft domains (Cordy et al,
2006), which are membrane regions enriched in cholesterol and
sphingolipids (Pike, 2009). While most of these domains are found
in the plasma membrane, intracellular lipid rafts have also been
described (Browman et al, 2006). One of these intracellular lipid
rafts is called mitochondria-associated ER membranes (MAM), a
functional subdomain of the ER located in close apposition to mito-
chondria that regulates key cellular metabolic functions (Vance,
2014).
We and others have shown that presenilins and c-secretase activ-
ity localize to MAM (Area-Gomez et al, 2009; Newman et al, 2014;
Schreiner et al, 2015). Moreover, MAM functionality (Area-Gomez
et al, 2012) and ER–mitochondrial apposition (Area-Gomez et al,
2012; Hedskog et al, 2013) are increased in AD.
We now report that the concentration of unprocessed C99 at the
MAM is increased in cell and animal models of AD and in cells from
AD patients. This increase in MAM-localized C99 is associated with
the activation of sphingolipid synthesis and hydrolysis, and with a
subsequent increase in ceramide levels [notably, a feature observed
in AD (Cutler et al, 2004; He et al, 2010), particularly in mitochon-
drial membranes (Kennedy et al, 2016)]. Finally, we show that
these higher levels of ceramide on mitochondria cause reduced
respiratory chain activity. Given these results, we propose that a
critical component of AD pathogenesis is mediated by C99 toxicity
through its effects on MAM and mitochondria.
Results
C99 inhibits mitochondrial respiration in presenilin-mutant cells
Current hypotheses regarding mitochondrial dysfunction in AD
propose that this defect is the consequence of the accumulation of
Ab in mitochondria (Manczak et al, 2006), but the mechanism is
unclear. To address this, we measured mitochondrial respiration in
fibroblasts from FAD patients with pathogenic mutations in PS1
(M146L and A246E) and in age-matched controls, as well as in mito-
chondria from the brain of a knock-in (KI) mouse model expressing
the M146V mutation in PS1 (PS-KIM146V) (Guo et al, 1999). We
observed reduced respiration in FAD patient cells (Fig 1A, and
Appendix Fig S1A and P) and in mitochondria isolated from
PS-KIM146V mouse brain (Appendix Fig S1B). To understand the
consequences of presenilin mutations and the effect of amyloid on
mitochondrial function in AD, we measured respiration in mouse
embryonic fibroblasts (MEFs) ablated for both Psen1 and Psen2
(PS-DKO) (Herreman et al, 2000). As above, we found decreased
respiration in the PS-DKO cells compared to controls (Fig 1B and
Appendix Fig S1Q). Additionally, measurements of oxygen
consumption rate (OCR) in permeabilized cultures of PS-DKO cells
showed clear defects in respiration (Appendix Fig S1D). Impor-
tantly, the decrease in respiration was not due to reductions in mito-
chondrial content or biogenesis (Appendix Fig S1C, F, G, and I).
Taken together, these results suggest that, from the mitochondrial
perspective, cells with pathological mutations in, and ablation of,
presenilins behave similarly, resulting in loss of mitochondrial respi-
ration. Given that PS-DKO MEFs lack c-secretase, these results
suggest that mitochondrial dysfunction in these mutant cells does
not depend on Ab production.
To determine whether mutations in presenilins affect mitochon-
dria via its role as the catalytic core of c-secretase, we measured
mitochondrial respiration in human neuroblastoma SH-SY5Y cells
treated with 10 lM of the c-secretase inhibitor DAPT. This inhibi-
tion caused a significant reduction in respiration compared to that
in untreated cells (Fig 1C and Appendix Fig S1R) without altering
mitochondrial content or biogenesis (Appendix Fig S1F, I, and J).
This result implies that the catalytic activity of presenilins is neces-
sary to maintain respiratory function. In addition, given that neither
PS-DKO nor DAPT-treated cells produce Ab, our results raise the
possibility that the mitochondrial deficits in AD are independent of
Ab production. However, it is equally possible that alterations in
full-length APP (FL-APP) or in any of its cleavage products may play
a role in regulating mitochondrial respiration. To test this, we
measured oxygen consumption in MEFs in which App and its
paralog Aplp2 were knocked out (APP-DKO) (Zhang et al, 2013).
Contrary to what we found in presenilin-mutant cells, elimination of
APP and APLP2 had no detrimental effects on respiration (Fig 1D).
In fact, the OCR in permeabilized APP-DKO cells was slightly but
significantly increased compared to that in controls (Fig 1D and
Appendix Fig S1E and T).
Considering that PS-DKO cells and APP-DKO cells both lack Ab
and AICD, our results suggest that the difference in mitochondrial
function observed in these two cell models was due to the presence
or absence of FL-APP or its cleavage products, C99 and C83. We
therefore measured respiration in PS-DKO cells treated with BACE1
inhibitor IV (BI) (Fig 1E and Appendix Fig S1S) and with an a-secre-
tase inhibitor (TAPI-1) (Appendix Fig S1H) to abrogate the produc-
tion of C99 and/or C83, respectively. As controls, we added back
physiological concentrations of Ab and oligomers of Ab42
(Appendix Fig S1K–M). Remarkably, only the treatment with BI
rescued the respiration defects, both in PS-DKO cells (Fig 1E and
Appendix Fig S1S) and in FAD fibroblasts (Appendix Fig S1N),
suggesting that increased levels of unprocessed C99, rather than the
levels of Ab, play a role in the mitochondrial dysfunction seen in AD.
Supporting this, addition of Ab oligomers to APP-DKO cells had little
effect on respiration (Appendix Fig S1M), whereas APP-DKO cells
expressing C99 suffered a significant decrease in respiration, which
was accentuated by adding DAPT (Fig 1D and Appendix Fig S1T),
without changes in the content of mitochondria (Appendix Fig S1O).
C99 can be localized in MAM
APP and its cleavage products have been shown to colocalize with
almost every membranous compartment in the cell, including
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mitochondria (Devi & Ohno, 2012). Thus, it is possible that in AD
cells, C99, as previously suggested for Ab (Casley et al, 2002), is
retained on mitochondrial membranes, disrupting its regulation.
To explore the localization of C99 and C83, we isolated subcellu-
lar fractions from mouse brain (Area-Gomez, 2014) (Appendix Fig
S2A) and analyzed them by Western blot [this was also validated in
an identical fractionation of mouse liver (Appendix Fig S2B)], using
specific markers for each compartment. Interestingly, we found that
APP-CTF fragments, while present in all compartments, were
enriched significantly in MAM regions of the ER (Fig 2A).
To discriminate between the localization of C83 and C99, we
isolated subcellular fractions from SH-SY5Y cells treated with DAPT
(to prevent cleavage of C99 and C83), or treated with a- and c-secre-
tase inhibitors (TAPI-1 and DAPT, to prevent the generation of C83
and the cleavage of C99, respectively, thereby revealing the pres-
ence only of C99). Notably, Western blot analysis of these fractions
showed that while C83 was present in all samples (i.e., cells treated
only with DAPT), C99 was located preferentially in MAM (i.e., frac-
tions from cells treated with TAPI-1 and DAPT) (Fig 2B).
Many reports have shown that C99 is localized mainly in endo-
somes (Haass et al, 2012; Das et al, 2016). Therefore, it is possible that
the presence of C99 in MAM regions was the result of a cross-contami-
nation of MAM samples with endosomes during the process of subcel-
lular fractionation. To eliminate this possibility, we isolated cellular
membranes from mouse brain and separated them through continuous
density sucrose gradients (Appendix Fig S2C), to allow us to purify
MAM away from endosomes and other subcellular fractions. After
gradient centrifugation, we examined the distribution of C83 and C99
compared to markers for other compartments (Fig 2C). Consistent
with the data of others (Das et al, 2016), FL-APP and BACE1 co-
migrated partially with a marker for endosomes (Rab7), but not with
lysosomal, ER-intermediate, or MAM markers (Fig 2C). Similarly, the
APP-CTFs C83 and C99 co-migrated with endosomal and lysosomal
markers (Rab5, Rab7, and LAMP-2) (Haass et al, 2012; Das et al,
2016), whereas PS1 co-migrated with MAM markers, such as FACL4
(Area-Gomez et al, 2009; Newman et al, 2014; Schreiner et al, 2015).
We reasoned that the difficulty in seeing APP-CTFs and PS1 together
was probably due to the rapid cleavage of the CTFs by c-secretase once
both are in the same compartment. Thus, to circumvent this rapid
cleavage and determine C99 localization, we repeated the same analy-
sis using PS-DKO cells (Herreman et al, 2000) in which APP-CTFs are
not cleaved, due to the absence of presenilins (Appendix Fig S1G).
Western blot analysis in this case showed that, in addition to its local-
ization in endosomes, a significant fraction of unprocessed C99 co-
migrated with MAMmarkers (Fig 2D).
To validate this result by imaging, we transfected wild-type (WT)
MEFs and COS-7 cells with plasmids expressing fluorescently tagged
C99 and mitochondrial and ER markers, and in the absence
(Appendix Fig S2D) or presence (Fig 2E) of c-secretase inhibitors.
Confocal microscopy analysis revealed that C99 (in red) was present
mainly in the cytosol and in ER membranes (in green), as shown
previously by others (Das et al, 2016). In addition to those sites,
C99 (in red) also colocalized with regions where both ER (in green)
and mitochondria (in blue) were present (white arrows in Fig 2E
and Appendix Fig S2D). This suggests that, like presenilins (Area-
Gomez et al, 2009), C99 can be localized to areas of the ER apposed
to mitochondria, that is, MAM, and is consistent with the fact that
c-secretase activity is present in this compartment (Area-Gomez
et al, 2009; Schreiner et al, 2015).
To corroborate this result, we analyzed the localization of unpro-
cessed C99 by immunogold electron microscopy (iEM) of PS-DKO
cells, using antibodies against C-terminal regions of APP. In agree-
ment with the confocal and Western blot analyses, iEM images indi-
cated that, when uncleaved, C99 can be localized in MAM regions
of the ER (Fig 2F and Appendix Fig S2E).
We next asked whether the increased localization of C99 in the
MAM also occurred in the context of AD, as tissues from AD
patients and animal models show increases in this fragment
(Holsinger et al, 2002). We measured C99 levels by Western blot in
homogenates from embryonic cortical neurons from WT and
PS1-KIM146V mouse brain (Guo et al, 1999) (Appendix Fig S2F), as
well as from cells from AD patients and controls (Appendix Fig
S2G). Notably, there was more C99 in the homogenates of mutant
neurons and of cells from AD patients, than in those from controls
(Appendix Fig S2F and G), similar to previous findings in other AD
patients and in FAD mice (McPhie et al, 1997; Yang et al, 2003;
Rockenstein et al, 2005). In addition, Western blot analysis of
subcellular fractions isolated from WT and PS-KIM146V mouse brain




Figure 1. Mitochondrial respiration [oxygen consumption rate (OCR)] in
c-secretase-deficient cells.
A Oxygen consumption rate in AD fibroblasts (FAD).
B Oxygen consumption rate in PS-DKO MEFs.
C Oxygen consumption rate in SH-SY5Y cells treated with DAPT, an inhibitor
of c-secretase activity.
D Oxygen consumption rate in APP-DKO MEFs before and after
overexpression of C99.
E PS-DKO MEFs treated with BACE inhibitor (BI).
Data information: Data represent averages of n > 5 independent experiments
 SD. *P < 0.05. Analysis by unpaired t-test.
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Figure 2. Localization of C99 to MAM.
A Western blot of fractions from mouse brain probed with the indicated antibodies (30 lg of protein per lane). PM, plasma membrane; CM, crude membrane fractions.
B Western blot of subcellular fractions from SH-SY5Y cells treated with a- and c-secretase inhibitors to reveal the differential localization of APP-CTF fragments. Note
that C99 is located predominantly in the MAM fraction (30 lg of protein per lane). Tot, Total homogenate.
C The crude membrane fraction (CM) from mouse brain was treated with detergent, purified on a continuous sucrose gradient, and gradient fractions were analyzed by
Western blot [two parallel gels (dotted line)], probing with antibodies to detect the indicated marker proteins. Blue dotted boxes indicate areas of the gradient
enriched in endosomal and lysosomal markers. Pink dotted boxes indicate areas of the gradient enriched in MAM markers.
D The same analysis using crude membrane fractions from PS-DKO MEFs to reveal the differential distribution of C83 vs. C99.
E Representative confocal image of a DAPT-treated COS-7 cell shows that uncleaved C99 (red) and mitochondria (blue) can colocalize only in those areas where ER
(green) is also present (i.e., MAM). Note how C99 colocalizes with areas where mitochondria and ER are apposed [white arrows in Merge (boxed), also shown in the
expanded view (Merge-Zoom)]. Scale bars = 20 lm in top panels, 10 lm in bottom (Merge-Zoom) panel.
F Representative immunoelectron microscopy image of PS-DKO cells incubated with antibodies against APP-CTF conjugated with immunogold particles, showing
retention of C99 in MAM areas of the ER. The ER is colored in green, and the mitochondrial outer membrane in red. Note significant labeling in MAM regions
(bracketed area, highlighted in inset).
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and especially in the MAM fractions, compared to that in controls
(Appendix Fig S2H), while the relative concentration of AICD was
not changed significantly (Appendix Fig S2H).
Taken together, our results suggest that C99, after being produced
in endocytic compartments (Das et al, 2016), is targeted to MAM,
via an as-yet unknown mechanism, to be cleaved rapidly by c-secre-
tase. Moreover, both pathogenic mutations in PS1 and reductions in
c-secretase activity cause the retention of this fragment in this region
of the ER that is in close apposition to mitochondria.
Increased localization of C99 at MAM upregulates MAM
functionality and ER–mitochondrial apposition
Given that reduced c-secretase activity causes an accumulation of
C99 at the MAM, we asked whether elevated C99 could be the cause
of the increased ER–mitochondria apposition and MAM upregula-
tion seen in AD (Area-Gomez et al, 2012). To assess apposition, we
transfected control and PS-DKO cells with markers of ER and mito-
chondria, and measured their colocalization (de Brito & Scorrano,
2008; Area-Gomez et al, 2012) in the absence or presence of BI to
prevent the generation of C99; remarkably, incubation with BI
rescued the upregulation of ER–mitochondria apposition seen in
mutant cells (Fig 3A and B).
To assess the effect of C99 on MAM functionality, we measured
the conversion of cholesterol to cholesteryl esters by ACAT1, a
MAM-resident enzyme (Area-Gomez et al, 2012), and monitored the
accumulation of newly synthesized cholesteryl esters in lipid
droplets (LDs) (Area-Gomez et al, 2012). Treatment with BI reduced
the incorporation of cholesterol into cholesteryl esters (Fig 3C) and
reduced the number of LDs in PS-DKO cells, in AD patient fibroblasts
(Fig 3D), and in PS1-KIM146V mouse astrocytes and cortical neurons
(Appendix Fig S3A). Similarly, treatment of PS-DKO cells with
Gleevec, an anticancer drug that has been recently shown to reduce
APP cleavage by BACE (Netzer et al, 2017), resulted in a significant
reduction of LDs in PS-DKO cells (Appendix Fig S3B). Lipid droplets
also accumulated in SH-SY5Y and HeLa cells treated with DAPT
alone (i.e., increasing C99), which was reversed in cells treated with
DAPT+BI (i.e., preventing C99 formation) (Appendix Fig S3C).
Supporting these data, and contrary to what we observed in c-secre-
tase-deficient cells but in agreement with what we saw in the
DAPT+BI treated cells, MEFs in which BACE1 had been knocked out
(Luo et al, 2001) were essentially devoid of LDs in the cytosol
(Appendix Fig S3D).
Taken together, these results show that the increase in, and
retention of, uncleaved C99 in the MAM induces both a physical
and functional enhancement of ER–mitochondria connections.
Sphingolipid metabolism is perturbed in AD-mutant cells
Given that MAM is a lipid raft (Area-Gomez et al, 2012), we specu-
lated that C99 could have a role in MAM activity and in ER–mito-
chondrial connectivity through changes in MAM lipid composition
(Simons & Vaz, 2004). We therefore performed lipidomic analyses
of total homogenates, mitochondrial fractions, and isolated MAM
from PS-DKO MEFs and controls. We found a significant increase in
ceramide (Fig 4A and Appendix Fig S4A, left panel) and a parallel
decrease in sphingomyelin in mutant cells (Fig 4B and Appendix Fig
S4B, right panel), which was more pronounced in the mitochondrial
(Fig 4A and B, and Appendix Fig S4B) and MAM (Fig 4C and
Appendix Fig S4C) fractions than in total homogenates. To confirm
the presenilin-dependent nature of these lipid alterations, we trans-
fected the PS-DKO cells with plasmids expressing either PS1WT or
PS1A246E (Appendix Fig S4D and E). Notably, expression of PS1WT,
but not PS1A246E, was capable of partially rescuing the alteration in
sphingolipid content in PS-DKO cells (Appendix Fig S4F).
Moreover, there was an inverse relationship between the
amounts of individual sphingomyelin species present and those of
the corresponding ceramide species (Appendix Fig S4G). The
latter result suggested that there was an increase in the hydrolysis
of sphingomyelin by sphingomyelinases (SMases) and subsequent
upregulation of the de novo synthesis of SM to replace its loss
(Fig 4D). In agreement with this idea, PS-DKO cells showed a
significantly higher synthesis of both ceramide and sphingomyelin
vs. WT (Fig 4D). In addition, acidic (aSMase) and neutral
(nSMase) SMase activities were increased in the PS-DKO cells
(Fig 4E), with a more dramatic upregulation of nSMase activity,
correlating with increased expression of neutral sphingomyelinase
2 (nSMase2; gene Smpd3) (Appendix Fig S4H). We also observed
increases in both acid and neutral SMase activities in PS1-KIM146V
mouse brain (Appendix Fig S4I). Likewise, we replicated the
increase in SMase activity in SH-SY5Y cells by inhibiting c-secre-
tase activity (Appendix Fig S4J), suggesting that the effects of
mutated presenilins on sphingolipid metabolism occur via their
roles as proteases in c-secretase. In agreement with this view and
with our lipidomics results, expression of PS1WT, but not
PS1A246E, significantly blunted the upregulation of nSMase activity
in PS-DKO cells (Appendix Fig S4K).
To understand whether these effects were direct or were mediated
by APP and/or its cleavage products, we measured SMase activity in
APP-DKO cells. Contrary to what we found in PS-DKO and DAPT-
treated cells, APP-DKO cells showed significant decreases in both
sphingolipid synthesis (Appendix Fig S4L) and SMase activities
(Appendix Fig S4M). As mentioned previously, both PS-DKO and
APP-DKO cells lack Ab and AICD. Therefore, any difference in sphin-
golipid regulation between the two cell types must be due to the
presence or absence of full-length APP and/or C83 and C99. We
therefore measured SMase activities in PS-DKO cells treated with
a- and b-secretase inhibitors to test the effect of C83 and C99, respec-
tively, as well as in PS-DKO cells in which Ab and AICD were added
back (Appendix Fig S4N). Interestingly, only the inhibition of C99
production (by BI) resulted in an attenuation of sphingolipid synthe-
sis and hydrolysis by sphingomyelinases (Fig 4E). These results indi-
cate that it is the increase in C99 that causes the upregulation of
sphingolipid metabolism, resulting in the previously described eleva-
tions in ceramide in AD (Filippov et al, 2012). However, they did not
clarify why ceramide is particularly elevated in MAM and mitochon-
drial membranes.
MAM participates in the regulation of sphingolipid metabolism
Previous reports have suggested that MAM is involved in regulating
sphingolipid metabolism, affecting mitochondrial activity (Ardail
et al, 2003). In fact, mitochondria are reported to contain ceramide,
probably generated at MAM (Kogot-Levin & Saada, 2014). Taking
these and our data into account, we hypothesized that an increase
in ceramide synthesis and in SMase activity at ER–mitochondria
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Figure 3. ER–mitochondrial apposition is regulated by C99.
A Localization of ER (green) and mitochondria (red) in the indicated MEFs without and with BACE1 inhibitor (inhibiting C99 formation; see Western in panel B). Large
boxes in the Merge are enlargements of the small boxes. Scale bars = 20 lm.
B Quantitation by ImageJ analysis of the colocalization of ER and mitochondrial signals from experiments like the one shown in (A) (average of n = 4 independent
experiments  SD). *P < 0.05. Analysis by unpaired t-test. The Western blot indicates the APP-CTF levels in the indicated cells (30 lg of protein per lane).
C ACAT1 activity in WT and PS-DKO MEFs in the presence and absence of a-, b-, and/or c-secretase inhibitors (average of n = 4 independent experiments  SD).
*P < 0.05. Analysis by unpaired t-test. ACAT activity was normalized by controls (WT incubated with vehicle [DMSO]).
D Staining of the indicated cells with LipidTox Green to detect lipid droplets. Scale bars = 20 lm.
ª 2017 The Authors The EMBO Journal Vol 36 | No 22 | 2017
Marta Pera et al Increased MAM-C99 causes mitochondrial dysfunction in AD The EMBO Journal
3361
Published online: October 10, 2017 
connections could explain the increased ceramide in mitochondrial
membranes in AD.
To address this, we analyzed ceramide synthesis and SMase
activity in vitro, using subcellular fractions from WT and PS-DKO
cells. The results indicate that MAM indeed participates in regulat-
ing sphingolipid metabolism (Fig 5A and Appendix Fig S5A). More-
over, SMase activities were upregulated significantly in subcellular
fractions from PS-DKO cells compared to controls (Fig 5A), as well
as in MAM from PS1-KIM146V mouse brain (Appendix Fig S5B). In
agreement with these results, Western blot analysis revealed a
remarkable increase in the localization of nSMase to MAM in
mutant cells compared to WT (Fig 5B), suggesting higher recruit-
ment of SMase to these ER–mitochondria contacts.
To explore this further, we incubated PS-DKO and control cells with
fluorescent sphingomyelin and analyzed its localization and conver-
sion to ceramide in mitochondrial membranes by thin-layer chro-
matography (TLC). Presenilin-mutant cells showed a substantial
decrease in fluorescent sphingomyelin intensity (Fig 5C) which was
paralleled by an increase in fluorescent ceramide (Fig 5C), implying
that upregulated SMase activity may be responsible for this inverse
behavior. Remarkably, the elevated deposition of ceramide at mito-
chondria disappeared when mutant cells were treated with BI (Fig 5C).
These data suggest that the effect of BACE1 inhibition in enhancing
mitochondrial respiration (Fig 1E and Appendix Fig S1N) may occur
via the attenuation of sphingolipid metabolism in mutant cells.
Why is there an increased recruitment of nSMase to these ER
regions in PS-mutant cells? It is well known that SMase activity is
modulated by membrane characteristics and lipid composition (De
Tullio et al, 2007). Notably, SMase activity is higher in lipid raft-like
domains, such as MAM, where liquid-ordered and liquid-disordered
phases coexist (Silva et al, 2009). In addition, nSMase shows
increased affinity for membranes enriched in anionic phospholipids
(Wu et al, 2011). In particular, the activity of nSMase2 is stimulated
upon its binding to phosphatidylserine (PtdSer) (Wu et al, 2011).
To see whether elevated PtdSer might be behind the increased




Figure 4. Sphingolipid metabolism in PS-DKO MEFs.
A, B Ceramide (A) and sphingomyelin (B) levels in total homogenate and in crude mitochondrial fractions in WT and PS-DKO MEFs. Lipid units are represented as molar
mass over total moles of lipids analyzed (mol%) (average of n = 5 independent experiments  SD).
C Ceramide and sphingomyelin levels in MAM isolated from WT and PS-DKO MEFs. Lipid units are represented as nmol/lg of protein over total nmoles of lipids
analyzed (average of n = 3 independent experiments  SD).
D De novo synthesis of ceramide (Cer) and sphingomyelin (SM) in WT and PS-DKO MEFs (average of n > 5 independent experiments  SD).
E Activities of acid (aSMase) and neutral (nSMase) sphingomyelinases before and after BI (average of n = 5 independent experiments  SD).
Data information: *P < 0.05. Analysis by unpaired t-test.
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Figure 5. MAM participates in the regulation of sphingolipid metabolism.
A Distribution of SMase activity in the indicated subcellular compartments in WT and PS-DKO MEFs. Note the overall increase in nSMase levels in the PS-DKO cells
(average of n = 5 independent experiments  SD). *P < 0.05. Analysis by unpaired t-test.
B Western blot of the indicated fractions from WT and PS-DKO MEFs (probed with antibodies against the indicated markers) to detect the levels of nSMase protein in
the indicated compartments (30 lg of protein per lane). TH, total homogenate; CM, crude membrane fraction.
C Sphingolipid levels in mitochondrial membranes extracted from the indicated cells after addition of fluorescent sphingomyelin (left, detection in TLC plates; right,
quantitation) (average of n = 5 independent experiments  SD). *P < 0.05 vs. WT levels. Analysis by unpaired t-test.
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the content of PtdSer in WT and PS-DKO homogenates and in
subcellular fractions. In agreement with our hypothesis, we found a
significant increase in the amount of PtdSer in PS-DKO membranes,
which was most pronounced in the MAM domains of the ER
(Appendix Fig S5C). This result also supports the idea that increases
in PtdSer due to C99-mediated upregulation of MAM are driving the
increased SMase activity in these ER regions. Consistent with this
proposed mechanism, inhibition of C99 production (with BI)
reduced the PtdSer content of PS-DKO membranes to control levels
(Appendix Fig S5D), while at the same time reversing the alterations
in both sphingomyelin (Appendix Fig S5E) and ceramide
(Appendix Fig S5F).
Taken together, we conclude that retention of uncleaved C99 in
MAM in presenilin-deficient cells upregulates both the synthesis and
catabolism of sphingomyelin in these regions of the ER, likely
accounting for the increased ceramide in mitochondrial membranes
(Fig 4A) via ER–mitochondrial connections.
Mitochondrial dysfunction in AD is caused by upregulated
sphingolipid turnover
The detrimental effects of ceramide on mitochondrial functionality
have been shown extensively (Kogot-Levin & Saada, 2014). Thus,
we speculated that the upregulation of SM turnover at MAM and the
subsequent local increase in ceramide could be the underlying cause
of the respiratory deficits seen in AD (Du et al, 2010; Swerdlow et al,
2014). To test this idea, we measured respiration in PS-DKO mutant
cells treated with 5 lM myriocin, a specific inhibitor of serine palmi-
toyltransferase, the first step in the de novo pathway to synthesize
sphingolipids, including ceramide. Inhibition of sphingolipid synthe-
sis by myriocin resulted in slight decreases in sphingomyelin
(Appendix Fig S6A) but in significant reductions in ceramide content
(Appendix Fig S6B) in our cell models, with changes in the latter
more pronounced in PS-DKO cells (Appendix Fig S6B). In agreement
with our hypothesis, this reduction in ceramide rescued the bioener-
getic defect in these mutant cells (Fig 6A).
Ceramide has been shown to provoke changes in mitochondrial
lipid composition, altering its membrane potential and permeability
(Kogot-Levin & Saada, 2014). Notably, the lipid composition of
mitochondrial membranes is crucial for the stabilization and assem-
bly of mitochondrial respiratory complexes into supercomplexes
(also called respirasomes) necessary for optimal respiratory chain
function (Acin-Perez & Enriquez, 2014). Therefore, it is possible that
ceramide interferes with bioenergetics by destabilizing or preventing
supercomplex assembly. To assess this, we used blue-native gel
electrophoresis (Acin-Perez et al, 2008) to examine the activity
(Fig 6B and C) and assembly status (Appendix Fig S6C and D) of
supercomplexes in mitochondria from WT and PS-DKO cells, from
DAPT-treated WT cells, and from PS-DKO cells incubated with BI
and myriocin (Fig 6B). Measurements by in-gel staining of the activ-
ities of respiratory chain complexes I and IV (Fig 6B and C) and
Western blotting to detect subunits of complexes I and III from PS-
DKO and DAPT-treated WT cells (Appendix Fig S6C and D) showed
a decrease in the activity of supercomplexes I+III+IV, I+III, and
III+IV, which could be rescued after treatment with BI and myriocin
(Fig 6D and E). Importantly, these changes in supercomplex activi-
ties and assembly were not due to alterations in the expression of
individual complex subunits (Appendix Fig S6E).
To corroborate these results in vivo, we analyzed mitochondrial
respiration and supercomplex activity in mitochondria isolated from
brain tissue from PS1-KIM146V mice at various ages (Appendix Fig S7A
and B). Interestingly, while MAM defects were already present in fetal
cortical neurons (Appendix Fig S3A), decreases in mitochondrial respi-
ration became significant only after 3 months of age (Appendix Fig
S7A). In agreement with our previous results, this bioenergetic defect
correlated with a significant decrease in supercomplex activity in
mutant samples compared to controls (Appendix Fig S7C and D).
Taken together, these results indicate that the bioenergetic
defects in AD are likely to be the consequence of upregulated sphin-
golipid turnover and increased ceramide content in mitochondria,
triggered by the retention of C99 at the MAM. This elevation in cera-
mide levels alters mitochondrial membrane properties, likely
hindering the assembly and activity of respiratory supercomplexes.
Moreover, these data suggest that while mitochondrial dysfunction
is an early and significant defect in AD, it is not a primary insult in
the pathogenesis of the disease, but rather is a consequence of
MAM dysfunction.
Discussion
In previous reports, we showed that c-secretase activity is localized
in MAM (Area-Gomez et al, 2009) and that alterations in c-secretase
activity result in the upregulation of MAM function and in increased
ER–mitochondria apposition (Area-Gomez et al, 2012). We now
show that the c-secretase substrate C99, in addition to its endosomal
localization, is also present in MAM domains. Thus, both the c-
secretase enzyme activity (i.e., presenilins) and its direct substrate
(i.e., C99) are located in the same compartment, where the former
can cleave the latter. Moreover, chemical and genetic alterations of
c-secretase activity provoke a significant increase in the amount of
this APP processing fragment in ER-MAM regions. The increased
presence of C99 in MAM causes the upregulation of MAM function-
ality (as measured by ACAT1 activity) and greater apposition
between ER and mitochondria. In addition, the higher concentration
of MAM-localized C99 induces the recruitment of sphingomyelinase
to this ER domain and the subsequent deregulation of sphingolipid
homeostasis, followed by mitochondrial dysfunction.
These results support a model in which, in addition to Ab,
increased C99 plays an early role in AD pathogenesis, via altered
MAM function. Of course, our results do not exclude the possibility
that C99 has other roles in the pathogenesis of AD. In fact, increases
in C99 were already shown to contribute to other aspects of the
pathogenesis of the disease (Saito et al, 2011; Lauritzen et al, 2012),
including endosomal dysfunction (Jiang et al, 2010), hippocampal
degeneration (Lauritzen et al, 2012), and altered Tau proteostasis
(Moore et al, 2015). In addition, elevations in C99 are toxic to
neurons (Neve et al, 1996), correlating with symptoms of the
disease (Rockenstein et al, 2005; Tamayev et al, 2012). Importantly,
we note that although much of our data were obtained using FAD
models and cells from FAD patients containing mutations in prese-
nilins, alterations in c-secretase activity and increased levels of C99
have been detected in sporadic AD patients as well (Fukumoto et al,
2002; Yang et al, 2003; Li et al, 2004; Pera et al, 2013).
We propose that, while the majority of C99 resides in endosomes,
C99 can traffic to MAM regions in the ER, where it is cleaved rapidly
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by c-secretase to produce Ab and AICD (Area-Gomez et al, 2009;
Schreiner et al, 2015). We note that although the mechanism by which
C99 translocates to ER-MAM is unknown, recent work has demon-
strated the existence of ER-endosome contacts (Rowland et al, 2014)
where lipid and protein exchange may occur (Wilhelm et al, 2017).
Thus, it is possible that C99 is delivered to ER via a similar mecha-
nism, where it regulates the interaction between ER and mitochondria.
Furthermore, the localization of C99 at MAM clarifies why C99, an ER-
localized protein (Matsumura et al, 2014), was also detected in mito-
chondria (Devi & Ohno, 2012). Similarly, since C99 processing occurs
at MAM, this could explain why Ab has been found to colocalize with
mitochondria (Hansson Petersen et al, 2008; Xie et al, 2013).
We show here that chemical or genetic alteration of c-secretase
activity results in an increase in unprocessed C99 in MAM. This, in
turn, provokes the recruitment of SMase activity to MAM and the
upregulation of sphingolipid turnover at these sites. These findings
have mechanistic implications. Specifically, one of the MAM func-
tions that is increased in AD is the synthesis of PtdSer by phos-
phatidylserine synthases 1 and 2 (PTDSS1/2) (Vance, 2014; Kannan
et al, 2017 #2382, Wu & Voelker, 2004; Area-Gomez et al, 2012
#234), resulting in higher levels of this phospholipid in MAM and
other membranes in AD cells and tissues. Considering the affinity of
nSMase for PtdSer (Wu et al, 2011), we believe that the activation
of nSMase by C99 is due, at least in part, to the upregulation of
PTDSS1/2 in MAM, triggered by the increased concentration of this
APP fragment. The details of this mechanism will require further
investigation.
These results also help clarify a number of previous observa-
tions. First, as MAM contains c-secretase and SMase activities, our




Figure 6. Mitochondrial dysfunction is the consequence of increased sphingolipid turnover.
A Respiratory chain deficiency [as measured by initial oxygen consumption rate (OCR)] in PS-DKO cells was rescued after treatment with myriocin (inhibitor of the de
novo sphingolipid synthesis pathway) (average of n = 3 independent experiments  SD). *P < 0.05, compared to WT; #P < 0.05, comparisons indicated on graph.
Analysis by unpaired t-test.
B, C In-gel complex I (B) and complex IV (C) activity staining in mitochondria from WT and PS-DKO cells after the indicated treatments.
D, E Quantification of specific bands shown in (B) and (C). Note that chemical or genetic inhibition of c-secretase results in decreased supercomplex I+III+IV activity.
This effect can be rescued by inhibition of C99 production [with a BACE1 inhibitor (BI)] or by inhibition of ceramide production with myriocin (Myr). Dotted lines
denote baseline levels (average of n = 3 independent experiments  SD). *P < 0.05 vs. baseline levels. Analysis by unpaired t-test.
Source data are available online for this figure.
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alterations in sphingolipid regulation (Filippov et al, 2012; Lee et al,
2014). Second, upregulation of SMase and the resulting increase in
ceramide are known to alter the size and composition of lipid raft
domains (Dinkla et al, 2012), such as MAM. Therefore, an increased
localization of C99 in MAM in AD may explain the upregulation of
ER–mitochondria connections and MAM functionality seen in the
disease (Area-Gomez et al, 2012; Hedskog et al, 2013). Finally,
given the detrimental effect of ceramide on mitochondrial super-
complex assembly and respiratory chain activity (Zigdon et al,
2013), we conclude that its accumulation is likely to be a primary
cause of mitochondrial dysfunction in AD.
This last conclusion disagrees with proposals that the accumula-
tion of Ab42 oligomers in mitochondria triggers the mitochondrial
defects seen in AD (Manczak et al, 2006). Rather, our results show
that PS-DKO and DAPT-treated cells, in which Ab production is
inhibited, can nevertheless recapitulate the mitochondrial deficits
seen in AD. This finding suggests that mitochondrial deficiencies are
due to increased levels of C99 rather than to elevated production of
longer Ab species, since bioenergetic deficiency can occur in the
absence of Ab. We believe that the discrepancy between our results
and those of others showing reductions in mitochondrial respiration
after incubation with Ab (Casley et al, 2002) is due mainly to the
use of unphysiologically high concentrations of this peptide (Casley
et al, 2002). Thus, we propose that MAM and mitochondrial alter-
ations are caused by an increased ratio of C99:Ab, rather than by an
increased ratio of Ab42:Ab40. In agreement with this, the increase of
C99 in mitochondria in AD has been described before, correlating
with mitochondrial respiratory defects that could be rescued by
partial deletion of BACE1 (Devi & Ohno, 2012). Finally, our results
linking C99, rather than higher levels of Ab42, to mitochondrial
dysfunction help explain how mitochondrial alterations can occur
early in AD pathogenesis (Balietti et al, 2013), preceding the appear-
ance of Ab-containing plaques (Yao et al, 2009).
In summary, our data demonstrate that increased levels of
unprocessed MAM-localized C99 are a driver of mitochondrial
dysfunction in AD, mediated by the loss of sphingolipid homeostasis
at ER–mitochondria connections. Equally important, while the
toxicity of Ab is undeniable, we suggest a role for elevated C99
(Rockenstein et al, 2005) and MAM deregulation (Schon & Area-
Gomez, 2010, 2013) in the pathogenesis of the disease, thus provid-
ing a new framework for understanding the link between alterations
in APP processing and lipid homeostasis as seminal effectors of AD
pathogenesis. Further work is required to fully elucidate the mecha-
nism by which MAM-C99 induces these alterations and validate its
relevance in the pathogenesis of this devastating disease.
Materials and Methods
Cells, animals, and reagents
AD and control cell lines were obtained from the Coriell Institute for
Medical Research (Camden, NJ, USA). SH-SY5Y and COS-7 cells
were obtained from the American Type Culture Collection. Other
PS1-mutant FAD cells were the kind gift of Dr. Gary E. Gibson
(Cornell University). WT, PS1-KO, PS2-KO, and PS1/2-DKO (called
PS-DKO) mouse MEFs were provided by Dr. Bart De Strooper
(University of Leuven). APP/APLP2-KO (called APP-DKO) (Herms
et al, 2004) and PS1-KIM146V knock-in mice (Guo et al, 1999). All
experiments were performed according to a protocol approved by
the Institutional Animal Care and Use Committee of the Columbia
University Medical Center and were consistent with the National
Institutes of Health Guide for the Care and Use of Laboratory
Animals. Mice were housed and bred according to international
standard conditions, with a 12-h light/12-h dark cycle, and sacri-
ficed at 3, 5, 7, 8, and 12 months of age. Brains were removed and
homogenized for Western blot and Seahorse analysis. All the experi-
ments were performed on at least three mice per group.
We used antibodies to ACAT1 (Abcam, ab39327), APP C-term-
inal (Sigma; A8717, polyclonal), APP-C99 [Covance; SIG-39320-200
(6E10), monoclonal], the a-subunit of mitochondrial ATP synthase
(complex V) (Invitrogen; 459240), the a-subunit of ATPase (Abcam,
ab7671), BACE1 (Cell Signaling; D10E5), CANX (Chemicon,
MAB3126), CDH2 (ref), complex I subunit NDUFA9 (Abcam;
ab14713), complex III subunit core-1-ubiquinol-cytochrome c reduc-
tase (Abcam; ab110252), OxPhos complex IV subunit IV (COX IV)
(Abcam; ab14744), Ergic53/p58 (Sigma; E1031), Erlin-2 (Cell Signal-
ing; #2959), ERp72 (Cell Signaling, D70D12), FACL4 (Abgent,
AP2536b), GM130 (BD Transduction Laboratories, 610822), G6PC
(ref), Lamp2 (Novus biologicals; NBP1-71692), Na+/K+ ATPase
(Abcam, ab7671), PEMT (a gift of Jean Vance, University of
Alberta), Presenilin 1 (Calbiochem; PC267; NOVUS biologicals;
EP1998Y), Rab5a (NOVUS Biologicals; NBP1-58880), Rab7a (Novus
Biologicals; NBP1-87174), TRAP-a (ref), nSMase (Thermo Scientific;
PA5-24614), total OXPHOS mouse cocktail (abcam, ab110413),
TOM20 (Santa Cruz; sc-11415), b-tubulin (Sigma; T4026), vinculin
(Sigma, V4505), and VDAC1 (Abcam; 34726). TLC silica plates were
from EMD Biosciences (5748-7). Ceramide (22244), sphingomyelin
(S0756), cholesteryl palmitate (C6072), cholesteryl oleate (C9253),
lipid markers for TLC (P3817), a-secretase inhibitor TAPI-1
(SML0739), cytochrome c from horse heart (C2506), 3,30-
diaminobenzidine tetrahydrochloride hydrate (D5637), GI254023X
(SML0789), b-secretase inhibitor IV (Calbiochem; 565788), c-secre-
tase inhibitor DAPT (D5942), antimycin A (A8674), FCCP (carbonyl-
cyanide p-(trifluoromethoxy)phenylhydrazone) (C2920), NADH
Grade II, disodium salt (Roche; 10128023001), nitro blue tetra-
zolium (N5514-25TA1), oligomycin (O4876), rotenone (R8875),
imatinib mesylate (Gleevec, SML1027), and serine palmitoyltrans-
ferase inhibitor myriocin (M1177) were from Sigma. Fluorescent
lipids BODIPY-FL C6 ceramide complexed to BSA (N22651) and
BODIPY-FL C12-sphingomyelin (D7711) were from Invitrogen. Radi-
olabelled 3H-serine and 3H-cholesterol were from Perkin Elmer; fatty
acid-free bovine serum albumin (FAF-BSA) was from MP Biomedi-
cal (820472). Amyloid b peptides 40 aa and 42 aa were from
Biopolymer Laboratory (UCLA), and AICD peptide was from Gene-
script Corporation (Piscataway, NJ, USA).
Seahorse analysis
Respirometry of cultured cells was performed using the XF24e Extra-
cellular Flux Analyzer (Seahorse Bioscience). Oxygen consumption
was measured in basal conditions (Seahorse media with 25 mM
glucose and 2 mM pyruvate) and after the sequential addition of
1 lM oligomycin (complex V inhibitor), 0.75 lM FCCP (uncoupler),
and 1 lM rotenone/1 lM antimycin A (complex I and complex III
inhibitors, respectively). All results were averages of five or more
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biological replicates. Every biological replicate consisted of three
technical replicates. For every technical replicate, we plated equal
number of cells (25,000 cell/well when MEFs were used, and 50,000
cells/well when human primary fibroblasts were analyzed). The
number of cells was also counted after every respirometry assay to
correct for cell death. All oxygen consumption (OCR) data were
normalized by the number of viable cells or by protein quantity
when isolated mitochondria were used.
For permeabilization assays, the cell culture medium was
replaced by the mitochondrial assay solution (70 mM sucrose,
220 mM mannitol, 5 mM KH2PO4, 5 mM MgCl2, 2 mM HEPES,
1 mM EGTA and 0.2% FAF-BSA, pH 7.4) containing 10 nM of the
XF Plasma membrane permeabilizer reagent XF PMP (Seahorse
Bioscience #102504-100) and pyruvate/malate (for complex I
assays) or succinate/rotenone (for complex II assays). Oxygen
consumption was measured at States 2, 3, 4, and uncoupling after
sequential addition of 3 mM ADP, 4 lM oligomycin, 6 lM FCCP,
and 4.5 lM Antimycin A.
To analyze mitochondrial respiration in mouse tissues, mito-
chondria were isolated from WT and PS1-KIM146V mouse brain.
Mouse brains were homogenized in ~10 volumes of homogenization
buffer (210 mM mannitol, 70 mM sucrose, 5 mM HEPES, and
1 mM EGTA) and then centrifuged at 900 × g for 10 min at 4°C.
The remaining supernatant was centrifuged at 9,000 × g for 10 min
at 4°C, and the resulting pellets were resuspended in washing buffer
(210 mM mannitol, 70 mM sucrose, 5 mM HEPES, 1 mM EGTA,
and 0.5% FAF-BSA pH 7.2) and centrifuged again at 8,000 × g for
10 min at 4°C. The pellets, containing mitochondria, were resus-
pended in mitochondrial assay solution, and protein was quanti-
tated using the BCA Protein Assay kit (Thermo Scientific #23227).
For complex I experiments, 8 lg of protein was added to each well
and for complex II analysis 6 lg per well. Analyses in the Seahorse
analyzer were performed as described in the permeabilization
assays.
Culture of primary mouse cortical neurons
Cortexes from four 14-day-old embryos were cut in pieces and
washed in 45% glucose in PBS. After that, brain tissues were
resuspended in 1 ml trypsin diluted in 45% glucose in PBS (1:1
v/v) and incubated at 37°C for 20 min. Samples were added to
500 ll horse serum and 10 units of DNase and incubated for
10 min at room temperature until debris sank to the bottom of
the tubes. The non-debris fraction was pelleted at 800 × g for
10 min and resuspended in Neurobasal Medium (Life Technolo-
gies; 21103-049) supplemented with 200 mM glutamine. Cells
were counted and seeded on coverslips coated with poly-ornithine
and laminin.
Plasmid constructs and transfections
Plasmids were constructed using standard techniques. In brief, APP
fragments AICD and C99 were amplified from pCAX APP-695
(Young-Pearse et al, 2007), using forward primer 50-cccgctagcctcgag
ATGCTGAAGAAGAAACAGTACACATCCATTC-30 for AICD, and 50-
cccggatccATGGATGCAGAATTCCGACATGACTC-30 for C99, with a
single reverse primer 50-cccggatccaagcttCTAGTTCTGCATCTGCT
CAAAGAACTTG-30 for both; restriction sites for subcloning are
underlined and the start/stop codons are in bold. The PCR products
were cut with XhoI+BamHI (for AICD) or with BamHI (for C99) and
subcloned into the corresponding sites in pGFP-N3 (Clontech). Plas-
mid C99-GFP was kind gift of Dr. Albert Lleo. For the construction
of this plasmid, C99 amplified from APP770 GFP using forward
primer_(Scott): (HindIII) 50 gcaagcttgcagaattccgacatgactcagga 30 and
reverse primer cw mini LRP 30 (psectag 2B mini LRP GFP primers).
The fragment was subcloned into psectag 2B with HindII/NotI. All
plasmids were verified by restriction analysis and sequencing. Cells
were transfected using LipofectamineTM Transfection Reagent
(Thermo Fisher Scientific, Life Technologies) according to the
manufacturer’s instructions.
Subcellular fractionation and Western blotting
Purification of ER, MAM, and mitochondria was performed and
analyzed as described (Area-Gomez et al, 2009). For C99 detection,
samples were run in 4–12% Bis–Tris gels (Criterion XT Precast Midi
Gels, BioRad) in XT MES buffer.
Electron microscopy analysis
Samples were fixed in 2.5% glutaraldehyde in 0.1 M sodium
cacodylate buffer, enrobed in 4% gelatin, postfixed with 1%
osmium tetroxide (aq) followed by 2% uranyl acetate, dehydrated
through a graded series of ethanol, and embedded in LX112 resin
(LADD Research Industries, Burlington, VT, USA). Ultrathin
sections were cut onto nickel grids with a Leica Ultracut UCT (Leica
Microsystems, Wetzlar, Germany).
Antigen retrieval immunolabeling
Sections were etched with saturated sodium metaperiodate for 1 h,
washed with PBS, blocked with 1% BSA, and incubated with
primary antibody overnight at 4°. The next day, they were washed
and then incubated in 6 nm goat anti-rabbit gold (Aurion, NL), for
2 h at room temperature. Sections were counterstained with uranyl
acetate and viewed on a JEOL JEM-1400Plus transmission electron
microscope at 120 kV.
Inhibition of a-, b-, and c-secretase activity
To inhibit c-secretase activity, cells were treated with 10 lM
DAPT, a highly specific inhibitor of this enzyme complex. For
b-secretase inhibition, cells were treated with 100 nM b-secretase
inhibitor IV (BI) or different doses of imatinib lysate (Gleevec).
To inhibit a-secretase, cells were treated with 5 lM of TAPI-1
(Enzo Life Sciences). Inhibition of aSMase and the nSMase activi-
ties was performed using 10 lM desipramine or 5 lM GW4869,
respectively. To inhibit serine palmitoyltransferase activity, the
cells were treated with 5 lM myriocin. Incubations with all drugs
were for 12–16 h.
Staining of lipid droplets
Staining of lipid droplets was performed using HCS LipidToxTM Deep
Green neutral lipid stain (Invitrogen H34475) according to the
manufacturer’s instructions. Lipid droplet staining was quantified
ª 2017 The Authors The EMBO Journal Vol 36 | No 22 | 2017
Marta Pera et al Increased MAM-C99 causes mitochondrial dysfunction in AD The EMBO Journal
3367
Published online: October 10, 2017 
using ImageJ. The different values represent the product of the
intensity and the area covered by the fluorescent signal above back-
ground in every cell examined.
Sphingolipid synthesis in cultured cells
Cells were incubated for 2 h with serum-free medium to ensure
removal of exogenous lipids. The medium was then replaced with
MEM containing 2.5 lCi/ml of 3H-serine for the indicated periods of
time. The cells were washed and collected in PBS, pelleted at
2,500 × g for 5 min at 4°C, and resuspended in 0.5 ml water,
removing a small aliquot for protein quantification. Lipid extraction
was done in three volumes of chloroform:methanol:HCl (2:1:0.5
v/v/v) added to the samples. Samples were vortexed and centri-
fuged at 8,000 × g for 5 min; the organic phase was blown and
dried under nitrogen. Dried lipids were resuspended in 30 ll of
chloroform:methanol (2:1 v/v) and applied to a TLC plate. Sphin-
golipids were separated using a solvent composed of chloroform/
methanol/0.22% CaCl2 (60:35:8 v/v/v). Development was performed
by exposure of the plate to iodine vapor. The spots corresponding to
the relevant sphingolipids (identified using co-migrating standards)
were scraped and counted in a scintillation counter (Packard
Tri-Carb 2900TR).
Lipidomic analyses
Lipids were extracted from equal amounts of material (30 lg
protein/sample). Lipid extracts were prepared via chloroform–
methanol extraction, spiked with appropriate internal standards,
and analyzed using a 6490 Triple Quadrupole LC/MS system (Agi-
lent Technologies, Santa Clara, CA) as described previously (Chan
et al, 2012). Glycerophospholipids and sphingolipids were separated
with normal-phase HPLC using an Agilent Zorbax Rx-Sil column
(inner diameter 2.1 × 100 mm) under the following conditions:
mobile phase A (chloroform:methanol:1 M ammonium hydroxide,
89.9:10:0.1, v/v/v) and mobile phase B (chloroform:methanol:water:
ammonium hydroxide, 55:39.9:5:0.1, v/v/v/v); 95% A for 2 min,
linear gradient to 30% A over 18 min and held for 3 min, and linear
gradient to 95% A over 2 min and held for 6 min. Quantification of
lipid species was accomplished using multiple reaction monitoring
(MRM) transitions that were developed in earlier studies (Chan
et al, 2012) in conjunction with referencing of appropriate internal
standards: ceramide d18:1/17:0 and sphingomyelin d18:1/12:0
(Avanti Polar Lipids, Alabaster, AL, USA). Values are represented
as mole fraction with respect to total lipid (% molarity). For this,
lipid mass (in moles) of any specific lipid is normalized by the total
mass (in moles) of all the lipids measured (Chan et al, 2012). In
addition, all of our results were further normalized by protein
content.
Analysis of sphingolipid synthesis in subcellular fractions
Cellular fractions were isolated from MEFs as described (Area-
Gomez et al, 2009). Two hundred micrograms was incubated in a
final volume of 200 ll of 100 mM HEPES pH 7.4, 5 mM DTT,
10 mM EDTA, 50 lM pyridoxal phosphate, 0.15 mM palmitoyl-
CoA, and 3 lCi/ml 3H-Ser for 20 min at 37°C. The reaction was
stopped by addition of three volumes of chloroform/methanol (2:1
v/v). Lipid extraction and TLC analysis were performed as described
above.
Analysis of sphingomyelinase activity
One hundred micrograms of protein was assayed in 100 mM of the
appropriate buffer (Tris/glycine for pH 7.0–9.0 and sodium acetate
for pH 4.0–5.0), 1.55 mM Triton X-100, 0.025% BSA, 1 mM MgCl2,
and 400 lM bovine brain sphingomyelin spiked with 22,000 dpm of
[3H]-bovine sphingomyelin (1 nCi/sample). Reactions were carried
out in borosilicate glass culture tubes at 37°C, overnight, followed
by quenching with 1.2 ml of ice-cold 10% trichloroacetic acid, incu-
bation at 4°C for 30 min, and centrifugation at 2,000 rpm at 4°C for
20 min. One milliliter of supernatant was transferred to clean tubes,
1 ml of ether was added, the mixture vortexed, and centrifuged at
2,000 rpm for 5 min. Eight hundred microliters of the bottom phase
was transferred to scintillation vials, 5 ml of Scintiverse BD (Fisher
Scientific, Fair Lawn, NJ, USA) was added, and samples were
counted.
ACAT activity assay
To measure cholesterol esterification in vivo, cultured cells were
incubated in serum-free medium for 2 h to remove all exogenous
lipids. After that, 2.5 lCi/ml of 3H-cholesterol was added to FBS-
free DMEM containing 2% FAF-BSA, allowed to equilibrate for at
least 30 min at 37°C, and the radiolabeled medium was added to
the cells for the indicated periods of time. Cells were then washed
and collected in DPBS, removing a small aliquot for protein quan-
tification. Lipids were extracted in three volumes of chloroform:
methanol (2:1 v/v). After vortexing and centrifugation at
8,000 × g for 5 min, the organic phase was blown to dryness
under nitrogen. Dried lipids were resuspended in 30 ll of chloro-
form:methanol (2:1 v/v) and applied to a TLC plate along with
unlabeled standards. A mixture of hexanes/diethyl ether/acetic
acid (80:20:1 v/v/v) was used as solvent. Iodine-stained bands
corresponding to cholesterol and cholesteryl esters were scraped
and counted.
Analysis of ER–mitochondrial apposition
Cells under were co-transfected with GFP-Sec61-b (Addgene plasmid
#15108) and DsRed2-Mito (Clontech, #632421) at a 1:1 ratio, using
Lipofectamine 2000 (Invitrogen, #11668-027) in serum-free DMEM.
Twelve hours post-transfection, cells were analyzed as described
(Guardia-Laguarta et al, 2014).
Preparation of synthetic Ab in different states of aggregation and
Ab40/Ab42 detection
Lyophilized Ab40 and Ab42 peptides (American Peptide; 62-0-80;
UCLA) were equilibrated at room temperature for 30 min and then
resuspended in hexafluoro-2-propanol (HIFP) (Sigma; H8508) to
1 mM using a glass-tight Hamilton syringe with Teflon plunger.
HIFP was allowed to evaporate in a fume hood and dried under
vacuum in a SpeedVac (Savant Instruments) and kept at 20°C.
Immediately prior to use, an aliquot was resuspended to 5 mM in
DMSO followed by bath sonication for 10 min.
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To analyze the effect of Ab addition, a mix of Ab40/Ab42 at a
ratio 10:1 was added to the cultured cells to a final concentration of
6,000 pg/ml for 24 h. For Ab42 oligomer formation, 5 mM of Ab42
in DMSO was diluted to 100 lM in ice-cold media, vortexed for
30 s, and incubated at 4°C for 24 h. Ab42 oligomers were added to
the cultured cells to a final concentration of 5 or 10 lM for 24 h.
Detection of Ab40/Ab42 levels in cell media was performed by
ELISA following manufacturer’s instructions (WAKO ELISA kit 294-
64701 for Ab40 and 292-64501 for Ab42).
Quantitative reverse transcription–polymerase chain
reaction (qRT–PCR)
Total RNA was extracted from MEFs using TRIzol Reagent (Invit-
rogen 15596-018) according to the manufacturer’s instructions and
was quantified by NanoDrop2000 (Thermo Scientific). One micro-
gram of total RNA was used to obtain cDNA by RT–PCR using a
High Capacity cDNA Reverse Transcription Kit (Applied Biosys-
tems; PN 4368813, 4374966). Real-Time PCR was performed in
triplicate in a StepOnePlusTM Real-Time PCR System (Applied
Biosystems; 4376600). The expression of each gene under study
was analyzed using specific predesigned TaqMan Probes (PGC-1a,
ppargc1a Mm01208835_m1; aSMase, smpd1 Mm00488319_g1;
nSMase, smpd3 Mm00491359_m1). The forward and reverse
primers (50?30) for Cox1 quantification were, respectively:
TGCTAGCCGCAGGCATTACT and CGGGATCAAAGAAAGTTGTGT
TT. The expression of each gene under study was analyzed using
specific predesigned TaqMan Probes and normalized against Gapdh
expression (Applied Biosystems, 4352339E) as an internal standard.
Supercomplex analysis
Analysis and quantification of mitochondrial respiratory complexes
by Western blot and enzymatic in-gel activity were carried out as
described (Acin-Perez et al, 2008).
Statistical analyses
All averages are the result of three or more independent experiments
carried out at different times with different sets of samples. Tests of
significance employed Student’s t-test at P < 0.05, unless indicated
otherwise; all error bars in the figures are  SD. For the determination
of ER–mitochondrial apposition, all images were taken randomly from
a set of multiple fields. The degree of colocalization was analyzed by
ImageJ, and data were compared using Mander’s coefficient.
Expanded View for this article is available online.
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